Good to see you stopping by! Maybe you can explain how a company like Vertex with all that it's invested in this project could publish incorrect data in October that is actually worse than what happened. Just don't get it.
Yes, but did you notice the difference between the interferon's. The Peg-Intron had a much lower response--Pegasys was the winner!
Yesterday my doc said he was hoping to participate in the Boceprevir trial but they will not. I asked why and he said Schering doesn't like him. He doesn't prescribe their drug enough. When I asked why, he said he felt the side effects were worse.
Wouldn't you think that one that is tougher to do would be the winner?
"Maybe you can explain how a company like Vertex with all that it's invested in this project could publish incorrect data in October that is actually worse than what happened. Just don't get it."
The same way they published incorrect data before that showed results were better than they actually were....LOL
I'm unaware of that latter -- maybe you can clue me in -- but at least that is understandable in a dark sort of way :)
Didn't notice but thanks for the heads up. That is something. Wonder if it's the drug or perhaps fewer drop-outs? I'm sure we'll hear more about that.
Am I crazy or are the numbers better, even having to be corrected? I'm being dense today I know, but I'm still pretty happy somewhere here on the inside....because the numbers are starting to show what most of us believed for a while now. Adding Telaprevir to SOC ups the odds of SVR to about, about, about 80% and those are extra percentages that I'll be glad to have next year when I try the re-tx.
We should all be doing a little dance, I think?
Hi Willow, numbers do look good and if they can get it approved for non responders next year it will definitely be dancing days.Hope you are well
Can you tell us how we can access the results?
I checked the Vertex website and could not find the data there. I am especially interested in the Prove 3 interim data for non responders.